ArticleFrontiers in public health2023
Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 17 citations in OpenAlex.
- Multicenter outbreak of plasmid-encodedAntimicrobial agents and chemotherapy · 2026Article
- Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children.BMC infectious diseases · 2026Article
- Isolation, characterization, and genomic analysis of a novel lytic bacteriophage with potent antibiofilm activity against multidrug-resistant Acinetobacter baumannii.BMC microbiology · 2026Article
- Antibiotic Resistance Profiles of Invasive Bacterial Isolates from Hospitalized Pediatric Patients in Serbia: A Multicenter Surveillance Study, 2020-2024.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical Characteristics of Carbapenem-Resistant Gram-Negative Bloodstream Infections and Fungemia Among High-Risk Pediatric Patients Receiving Empirical Antifungal Therapy.Pathogens (Basel, Switzerland) · 2026Observational
- Integrated clinical and genomic characterization ofJournal of medical microbiology · 2026Article
- Linalool exhibits potent antibacterial and anti-biofilm activity against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Risk factors for carbapenem-resistant Acinetobacter baumannii infection in children and A. baumannii-related mortality in the PICU: a retrospective study in Guangxi, China.BMC infectious diseases · 2026Article
- Root Cause Analysis for Outbreaks of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Clonal patient-to-patient spread is associated with multidrug-resistantFrontiers in medicine · 2026Article
- Low-dose sulbactam-durlobactam for recurrent CRAB pneumonia in a child with cerebral palsy: a Case Report from a resource-limited setting.Frontiers in pharmacology · 2026Article
- Phenotypic and Genotypic Characterization of Carbapenem-ResistantInternational journal of microbiology · 2026Article
- Development and validation of an interpretable machine learning-based model for predicting carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Decoding GuaB: Machine Learning-Powered Discovery of Enzyme Inhibitors Against the SuperbugPharmaceuticals (Basel, Switzerland) · 2025Article
- Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study.Annals of African medicine · 2025Article
- Clinical and Epidemiological Aspects on Healthcare-Associated Infections withMedicina (Kaunas, Lithuania) · 2025Article
- Relationship between antibiotic resistance and biofilm-forming capacity with RND efflux pumps expression in clinical Acinetobacter baumannii isolates.Archives of microbiology · 2025Article
- CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Exploring the clinical outcomes and molecular characteristics ofFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Carbapenem-resistant Methods: From January 2016 to December 2021, all children diagnosed with nosocomial Results: During the 6-year study period, a total of 372 episodes of nosocomial Conclusions: This study highlights considerable incidence rate and remarkable mortality of children with
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.